Toll (TOL) (ASML) (CBE) (BRFS) (SVNT) Upgraded

Toll Brothers, Inc. (NYSE: TOL), ASML Holding (NASDAQ: ASML), Cooper Industries PLC (NYSE: CBE), BRF Brasil Foods (NASDAQ: BRFS) and Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) upgraded by analysts.

Goldman Sachs (NYSE:GS) upgraded Toll Brothers (TOL) from a "Neutral" rating to a “buy” rating. They have a price target of $25.00 on the company.

Deutsche Bank (NYSE:DB) upgraded ASML Holding (ASML) from a "Buy" rating to a “hold” rating.

Raymond James (NYSE:RJF) upgraded BRF Brasil Foods (BRFS) from an “underperform” rating to a “market perform” rating.

Citigroup (NYSE:C) upgraded Cooper Industries PLC (CBE) to a “Buy” rating.

Leerink upgraded Savient Pharmaceuticals, Inc. (SVNT) from an “underperform” rating to a “market perform” rating.

Ratings on (RADS) (SPLS) (SVNT) (TE) (TEF) (ZOLT) Downgraded

Analysts downgraded their ratings on Radiant Systems Inc (NASDAQ: RADS), Staples, Inc. (NASDAQ: SPLS), Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), TECO Energy, Inc. (NYSE: TE), Telefonica SA (NYSE: TEF) and Zoltek Companies, Inc. (NASDAQ: ZOLT) today.

Sidoti downgraded Radiant Systems Inc (RADS) from a “buy” rating to a “neutral” rating.

Nomura downgraded Staples, Inc. (SPLS) from a “neutral” rating to a “reduce” rating.

Lazard Capital downgraded Savient Pharmaceuticals, Inc. (SVNT) from a “buy” rating to a “neutral” rating.

Bank of America (NYSE:BAC) downgraded shares of TECO Energy, Inc. (TE) from a “neutral” rating to an “underperform” rating.

Deutsche Bank (NYSE:DB) downgraded Telefonica SA (TEF) from a “buy” rating to a “hold” rating.

Craig Hallum downgraded Zoltek Companies, Inc. (ZOLT) from an “accumulate” rating to a “neutral” rating.

Ratings on (SPR) (SVNT) (WEST) (WRC) (OMPI) Downgraded

Ratings on AeroSystems Holdings, Inc. (NYSE: SPR), Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), Westinghouse Solar (NASDAQ: WEST), The Warnaco Group, Inc. (NYSE: WRC) and Obagi Medical Products, Inc. (NASDAQ: OMPI) downgraded by analysts today.

Bank of America (NYSE:BAC) downgraded Spirit AeroSystems Holdings, Inc. (SPR) from a “buy” rating to a “neutral” rating. They have a price target of $26.00 on the company.

JPMorgan Chase & Co. (NYSE:JPM) downgraded Savient Pharmaceuticals, Inc. (SVNT) from an “overweight” rating to a “neutral” rating.

Ardour Capital downgraded Westinghouse Solar (WEST) from a “buy” rating to a “hold” rating. They have a price target of $2.00 on the company, down from $3.00.

Piper Jaffray downgraded The Warnaco Group, Inc. (WRC) from an “overweight” rating to a “neutral” rating. They have a price target of $61.00 on the company.

Robert W. Baird downgraded Obagi Medical Products, Inc. (OMPI) from an “outperform” rating to a “neutral” rating. They have a price target of $9.00 on the company, down from $15.00.

Ratings On (SMSI) (SVNT) (UN) Downgraded

Ratings on Smith Micro Software, Inc. (NASDAQ: SMSI), Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and Unilever NV (NYSE: UN) downgraded by analysts.

Merriman Curhan Ford downgraded Smith Micro Software, Inc. (SMSI) from a “buy” rating to a “neutral” rating.

JMP Securities downgraded Savient Pharmaceuticals, Inc. (SVNT) from an “outperform” rating to a “market perform” rating.

Credit Suisse (NYSE:CS) downgraded shares of Unilever NV (UN) from a “neutral” rating to an “underperform” rating.

Savient Pharmaceuticals (NASDAQ:SVNT) Must Wait for KRYSTEXXA Benefits

Savient Pharmaceuticals (NASDAQ:SVNT) has shipped KRYSTEXXA to specialty distributors starting on December 1, but won't enjoy the benefits of the launch until sometime in the middle of January 2011.

Global Hunter Securities, which maintains a "Buy" rating on Savient, considers the company highly undervalued.

"SVNT announced the wholesale acquisition cost (WAC) of KRYSTEXXA of $2,300/8 mg vial. In addition, the company commenced shipment of drug to specialty distributors. Although KRYSTEXXA will be available by prescription on December 1st, we do not foresee significant KRYSTEXXA sales until the sales representatives are on board in mid-January. We continue to believe KRYSTEXXA could become a best-in-class therapy with its differentiated profile and represent a new treatment paradigm for this unmet need to warrant a $500 million peak potential by 2016," said Global Hunter.

Savient closed Wednesday at $12.08, gaining $0.28, or 2.37 percent. Global raised their price target on them from $15 to $19.